Estradiol + Medroxy Progesterone Acetate — Competitive Intelligence Brief

Estradiol + Medroxy Progesterone Acetate (Estradiol + Medroxy Progesterone Acetate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hormone replacement therapy (HRT). Area: Endocrinology / Women's Health.

marketed Hormone replacement therapy (HRT) Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR) Endocrinology / Women's Health Small molecule

Target snapshot

Estradiol + Medroxy Progesterone Acetate (Estradiol + Medroxy Progesterone Acetate) — Erasmus Medical Center. This combination provides estrogen replacement and progestin supplementation to manage menopausal symptoms and prevent endometrial hyperplasia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Estradiol + Medroxy Progesterone Acetate TARGET	Estradiol + Medroxy Progesterone Acetate	Erasmus Medical Center	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)
Estracomb TTS	Estracomb TTS	Anna Posadzy-Małaczyńska	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)
Tibolone plus Xiangshao granules	Tibolone plus Xiangshao granules	Peking Union Medical College Hospital	marketed	Hormone replacement therapy (HRT) / Selective tissue estrogenic activity regulator (STEAR)	Estrogen receptor, Progesterone receptor, Androgen receptor
Femoston® 1, Femoston® 2	Femoston® 1, Femoston® 2	Scientific Research Institute of Public Health, Russian Federation	marketed	Hormone replacement therapy (HRT)	Estrogen receptor (ER-α, ER-β) and progesterone receptor (PR)
Transdermal estrogen	Transdermal estrogen	University of Utah	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estradiol+MPA	Estradiol+MPA	Brigham and Women's Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha and beta; progesterone receptor
estradiol plus progesterone	estradiol plus progesterone	Peking Union Medical College Hospital	marketed	Hormone replacement therapy (HRT)	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hormone replacement therapy (HRT) class)

1. Anna Posadzy-Małaczyńska · 1 drug in this class
2. Beni-Suef University · 1 drug in this class
3. Brigham and Women's Hospital · 1 drug in this class
4. El Shatby University Hospital for Obstetrics and Gynecology · 1 drug in this class
5. Erasmus Medical Center · 1 drug in this class
6. Massachusetts General Hospital · 1 drug in this class
7. Myovant Sciences GmbH · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. Scientific Research Institute of Public Health, Russian Federation · 1 drug in this class
10. Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 1 drug in this class